Rocket Pharmaceuticals says FDA aligns on Danon disease pivotal trial path
The FDA confirmed a 12-patient pivotal population, a recalibrated dose, and 12-month co-primary endpoints for RP-A501 in Danon disease.
SEC filing
Latest
3 stories
Tuesday, September 15
Thursday, August 27
Rocket Pharmaceuticals adopts new severance program, signs executive employment deals
The board approved a severance and change-in-control program for U.S. employees and entered new employment agreements with CEO Gaurav Shah and General Counsel Martin Wilson.
SEC filing
Monday, August 10
Rocket reports Danon safety clearance and $180M PRV sale in Q2 2026 update
All three initial Danon disease patients cleared safety observation under Rocket's modified Phase 2 protocol, as the company sits on $283.7 million in cash after monetizing its priority review voucher.
SEC filing